vTv Therapeutics (VTVT) FCF Margin (2014 - 2026)

vTv Therapeutics has disclosed FCF Margin across 11 years of filings, most recently posting 24.85% for Q1 2026.

• FCF Margin for Q1 2026 came in at 24.85%, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was 28.27% (up 13914232.0% YoY), and the FY2024 annual result was 2488.4%, changed N/A from the prior year.
• FCF Margin came in at 24.85% for Q1 2026 at vTv Therapeutics, up from 28382.35% in the prior quarter.
• In the past five years, FCF Margin ranged from a high of 7844.44% in Q2 2022 to a low of 76444.44% in Q4 2022.
• The 3-year median for FCF Margin is 392.28% (2022), against an average of 16290.34%.
• Peak annual rise in FCF Margin reached 5226667 bps in 2022, while the deepest fall reached 514444 bps in 2022.
• vTv Therapeutics' FCF Margin stood at 76444.44% in 2022, then jumped by 63 bps to 28382.35% in 2024, then jumped by 100 bps to 24.85% in 2026.
• The last three FCF Margin figures came in at 24.85% (Q1 2026), 28382.35% (Q4 2024), and 733.5% (Q1 2024), per Business Quant data.